Hyloris Successfully Raises EUR 15.0 Million in an Equity Offering by Means of A Private Placement Via an Accelerated Bookbuild Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

PRESS RELEASE

REGULATED INFORMATION – INSIDE INFORMATION

1 April 2022, 07:00 CET

LIÈGE, Belgium , April 01, 2022 (GLOBE NEWSWIRE) --  Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) (the “Company” or “Hyloris”), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces today that it successfully raised an amount of EUR 15.0 million in gross proceeds, from new and existing, local and international investors, through an equity offering by means of a private placement via an accelerated bookbuild offering of 967,742 new shares (being approximately 3.7% of the Company's outstanding shares (pre-transaction)) at an issue price of EUR 15.50 per share (the "Offering"), representing a discount of 1.6% to the 30-day VWAP.

Stijn Van Rompay, Chief Executive Officer and co-founder of Hyloris, commented: “We are delighted to have completed this transaction at a tight discount in challenging market conditions, and are particularly pleased with the continued strong support from our existing investors as well as welcoming new investors. This transaction further strengthens our financial position as we continue to drive forward our pipeline of repurposed drugs in areas of high unmet medical needs and endeavour to grow shareholder value. We are excited for the year ahead where we plan to add four new innovative product candidates to our pipeline.”

Hyloris will use the net proceeds of the Offering primarily to fund the development of new products and accelerate in-house R&D activities.

Joh. Berenberg, Gossler & Co. KG (“Berenberg”), KBC Securities NV ("KBC Securities") and Stifel Nicolaus Europe Limited (“Stifel”) are acting as Joint Global Coordinators and Joint Bookrunners in the Offering (jointly, the "Underwriters").

The new shares have been placed with certain qualified and/or institutional investors as provided in the applicable laws and regulations and certain other investors who acquired new shares for a total consideration of at least €100,000 per investor.

The payment and delivery of the new shares is expected to take place on 5 April 2022,